Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ES16001
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of ES16001 in Patients With COVID-19
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
September 01, 2022
Lead Product(s) : ES16001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ES16001
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Ordi Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Genencell Signs Accord With UAE Partner to Distribute Covid-19 Pills
Details : The two companies first aim to receive approval for ES16001 as a biopharmaceutical over-the-counter (OTC) drug without additional clinical trials in Turkey. They then will move on to obtain additional approval as an ethical drug (ETC).
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
May 24, 2022
Lead Product(s) : ES16001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Ordi Pharma
Deal Size : Undisclosed
Deal Type : Agreement